{
  "timestamp": "2025-07-28 09:43:05",
  "user_analysis": {
    "adjusted_ebitda_2024": 687.63,
    "owner_comp_addback": 300,
    "revenue_2024": 3726,
    "gross_profit_2024": 2623,
    "blended_rates": [
      8.0,
      9.0,
      10.0,
      11.0,
      12.0
    ],
    "implied_valuations": [
      4813,
      4444,
      3569,
      860
    ],
    "cash_percentages": [
      66.4,
      62.6,
      52.6,
      81.8
    ],
    "equity_percentages": [
      32,
      37,
      47,
      18
    ]
  },
  "our_baseline": {
    "normalized_ebitda": 1649,
    "enterprise_value": 9070,
    "equity_value": 6920,
    "expected_irr": 0.138,
    "recommendation": "STRONG BUY"
  },
  "differences_analysis": {
    "ebitda_variance": {
      "user_ebitda": 687.63,
      "our_ebitda": 1649,
      "variance": 961.37,
      "variance_pct": 1.39809199714963
    },
    "valuation_approach": {
      "user_method": "Blended rate / cash flow approach",
      "our_method": "EV/EBITDA multiple with Monte Carlo validation",
      "user_range": "$860K - $4,813K",
      "our_valuation": "$6,920K"
    },
    "methodology_differences": [
      "User focuses on cash flow yield approach",
      "Our analysis uses industry multiple validation",
      "User appears to model debt/equity structure scenarios",
      "Our analysis emphasizes risk-adjusted returns"
    ]
  },
  "ebitda_reconciliation": {
    "base_operating_income": 1432,
    "our_total_adjustments": 217,
    "user_total_adjustments": -744.3699999999999,
    "our_final_ebitda": 1649,
    "user_final_ebitda": 687.63,
    "key_difference_source": "Marketing normalization approach"
  },
  "valuation_comparison": {
    "user_methodology": {
      "approach": "Cash-on-cash / Blended rate methodology",
      "blended_rates": [
        8.0,
        9.0,
        10.0,
        11.0,
        12.0
      ],
      "strengths": [
        "Focuses on actual cash returns to investor",
        "Models different leverage scenarios",
        "Provides sensitivity across financing structures"
      ],
      "limitations": [
        "May not capture full business risk profile",
        "Doesn't account for exit multiple expansion",
        "Limited consideration of operational improvements"
      ]
    },
    "our_methodology": {
      "approach": "EV/EBITDA multiple + Monte Carlo validation",
      "base_multiple": 5.5,
      "expected_irr": 13.8,
      "strengths": [
        "Industry-standard comparative valuation",
        "Risk-adjusted probabilistic modeling",
        "Comprehensive operational analysis",
        "Exit strategy optimization"
      ],
      "limitations": [
        "Multiple-based may not reflect unique value",
        "Complex model may obscure key drivers"
      ]
    },
    "user_implied_multiples": [
      6.999403749109259,
      6.462777947442666,
      5.190291290374184,
      1.2506726000901647
    ],
    "our_multiple": 5.5,
    "convergence_analysis": {
      "ebitda_band": {
        "low": 687.63,
        "high": 1649,
        "midpoint": 1168.315
      },
      "valuation_overlap": {
        "our_val_at_user_ebitda": 3781.965,
        "user_val_closest_to_ours": 4813,
        "convergence_range": "$3,782K - $4,813K"
      },
      "recommended_synthesis": {
        "recommended_ebitda": 1168.315,
        "valuation_approach": "Hybrid multiple + cash flow validation",
        "key_insights": [
          "User's cash flow focus validates investment returns",
          "Our multiple approach provides market context",
          "EBITDA normalization needs alignment on marketing",
          "Both approaches support investment viability"
        ],
        "action_items": [
          "Reconcile marketing expense normalization methodology",
          "Validate owner compensation adjustment amount",
          "Stress test both approaches under different scenarios",
          "Combine cash flow discipline with multiple benchmarking"
        ]
      }
    }
  },
  "overall_assessment": {
    "ebitda_accuracy_score": 0,
    "methodology_soundness_score": 0.85,
    "overall_grade": "B+",
    "strengths": [
      "Systematic owner compensation adjustment",
      "Cash flow focused approach shows return discipline",
      "Multiple scenario sensitivity analysis",
      "Professional Excel structure and layout"
    ],
    "improvement_areas": [
      "Marketing expense normalization methodology",
      "Industry multiple benchmarking integration",
      "Risk-adjusted return analysis",
      "Monte Carlo sensitivity testing"
    ],
    "validation_status": "PARTIALLY VALIDATED - NEEDS REFINEMENT"
  },
  "recommendations": [
    "EBITDA Reconciliation: Align marketing normalization to 14% industry standard (+$483K impact)",
    "Valuation Synthesis: Combine cash flow approach with EV/EBITDA multiple validation",
    "Risk Analysis: Add Monte Carlo simulation to validate return expectations",
    "Market Context: Benchmark against recent medispa transaction multiples",
    "Integration Planning: Incorporate 100-day value creation roadmap",
    "Due Diligence: Add management retention analysis to cash flow projections",
    "Exit Strategy: Model different exit scenarios with probability weighting"
  ]
}